8-K current report · filed Nov 4, 2026

PHIBRO ANIMAL HEALTH CORP (PAHC) 8-K Current Report: November 4, 2026

Item 2.02Item 5.07Item EX-99.1PAHC overview

Short answer

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.07 (Submission of Matters to a Vote of Security Holders), Item EX-99.1 (Exhibit EX-99.1). Press release covers fiscal Q1 ended September 30, 2026 operating results.

PHIBRO ANIMAL HEALTH CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers fiscal Q1 ended September 30, 2026 operating results
  • Fiscal 2027 guidance announced for the year ending June 30, 2027
  • Investors should review Exhibit 99.1 for earnings figures and outlook details

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • 98.8% of voting power represented, ensuring a valid quorum for shareholder decisions
  • All three Class I nominees elected through 2029, including Daniel Bendheim, Jonathan Bendheim, and Sam Gejdenson
  • Director support remained strong, with 204.2 million to 208.2 million votes for each nominee
  • PwC auditor selection ratified for fiscal 2027, with 212.2 million votes for and 1.3 million against
  • Class B shares carry 10 votes each versus one for Class A, concentrating voting influence among Class B holders

Item EX-99.1 · Exhibit EX-99.1

  • Q1 FY2027 sales $386.8M, up 6%, with Mineral Nutrition up 17% and Performance Products up 16%
  • Net income $29.5M, up 11%, and adjusted EPS $0.79, up 8%, despite SG&A rising 15%
  • Adjusted EBITDA $64.3M, up 4%, led by Mineral Nutrition and Performance Products, while Animal Health EBITDA declined 1%
  • FY2027 guidance maintained: sales $1.55B-$1.60B and adjusted EBITDA $258M-$268M
  • Brazil virginiamycin approval remains upside potential, but guidance assumes no additional sales for the rest of FY2027
  • Balance-sheet focus: $739.6M debt, 2.9x gross leverage, and management prioritizing inventory reduction and cash conversion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PHIBRO ANIMAL HEALTH CORP 8-K filings

Get the next PAHC 8-K as it lands

Follow PAHC for push alerts, or ask the research agent what this filing means.